Freshleaf and TGA

The TGA is re-examining the clinical evidence for medical cannabis – including over-the-counter CBD

The TGA is re-examining the clinical evidence for medical cannabis – including over-the-counter CBD This is the third article in our series about the Department of Health’s submission to the Senate Inquiry into medical cannabis patient access. You can read the Department’s submission here. In December 2017 the TGA, in collaboration with several universities, produced...
Read More
FreshLeaf Analytics Graphic 3

Department of Health releases new medical cannabis patient access info

Department of Health releases new medical cannabis patient access info The TGA tends to avoid speaking about prescriptions because they have no direct oversight regarding scripts. Instead they focus on SAS-A/B approvals and AP notifications. These can be considered proxy figures for access. And if you have empirical data about prescriptions per approval, and empirical...
Read More
Department of Health

Department of Health provides new commercial insights to Senate Inquiry

Department of Health provides new commercial insights to Senate Inquiry The Senate Inquiry into the current barriers to patient access to medicinal cannabis in Australia has already revealed some fascinating new pieces of information on the performance of our medical cannabis framework. Public submissions to the Inquiry are available on the APH website and they...
Read More
FreshLeaf’s top ten 2020 trends for Australia’s medical cannabis industry

FreshLeaf’s top ten 2020 trends for Australia’s medical cannabis industry

FreshLeaf’s top ten 2020 trends for Australia’s medical cannabis industry You don’t need a crystal ball to know that 2020 is going to be a big year for cannabis in Australia and around the world. But what does that mean exactly for companies, patients and regulators? Here are the top 10 most important trends in...
Read More